A33 CLINICAL STUDIES IN OBSTRUCTIVE LUNG DISEASE: Reduction In Airway Eosinophils In Patients With COPD Treated With Roflumilast For 16 Weeks: A Double-Blind, Parallel-Group, Randomized, Placebo-Controlled Biopsy Trial

A33 CLINICAL STUDIES IN OBSTRUCTIVE LUNG DISEASE: Reduction In Airway Eosinophils In Patients With COPD Treated With Roflumilast For 16 Weeks: A Double-Blind, Parallel-Group, Randomized, Placebo-Controlled Biopsy Trial

The aim of the ROflumilast Biopsy European Research Trial (ROBERT [NCT01509677]), an exploratory, double-blind, parallel-group, randomized, placebo-controlled trial, was to assess the anti-inflammatory effects of roflumilast on bronchial mucosal inflammation in patients with moderate-to-severe COPD...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Hauptverfasser: Rabe, K, Saetta, M, Watz, H, Baraldo, S, Hanauer, G, Göhring, U-M, Delgadillo, J, Roman, J, Alagappan, V
Format: Artikel
Sprache:eng
Schlagworte:
Biopsy
Chronic obstructive pulmonary disease
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The aim of the ROflumilast Biopsy European Research Trial (ROBERT [NCT01509677]), an exploratory, double-blind, parallel-group, randomized, placebo-controlled trial, was to assess the anti-inflammatory effects of roflumilast on bronchial mucosal inflammation in patients with moderate-to-severe COPD (GOLD stage M-III). Over the 16-week treatment period, roflumilast was associated with a 47% reduction in the number of eosinophils in bronchial biopsy samples compared with placebo (0.53 [95% CI 0.34, 0.82], p=0.0046, Table, Poisson regression).
ISSN:1073-449X
1535-4970